Zobrazeno 1 - 10
of 43
pro vyhledávání: '"B. J. Vos"'
Autor:
B J, VOS
Publikováno v:
Antibioticschemotherapy (Northfield, Ill.). 6(3)
Cyclin D1 gene amplification and overexpression are present in ductal carcinomain situ of the breast
Publikováno v:
Journal of pathology, 187(3), 279-284. John Wiley and Sons Ltd
Cyclin D1 (CCND1) amplification is found in 10-15 per cent of invasive breast carcinomas, but it is not well established whether this gene alteration also occurs in the precursor of invasive breast carcinoma, ductal carcinoma in situ (DCIS). By South
Publikováno v:
Transplantation. 64:1097-1101
Background Graft-versus-host disease (GVHD) remains the most significant obstacle to the use of allogeneic bone marrow transplantation as a treatment for leukemia and other hematological malignancies. Because current GVHD treatment regimens such as c
Autor:
A. M. Cleton-Jansen, C. B. J. Vos, Johannes L. Peterse, M.J. van de Vijver, Sergey V. Litvinov, W. J. F. De Leeuw, Geert Berx, Cees J. Cornelisse, F. Van Roy
Publikováno v:
Journal of pathology, 183(4), 404-411. John Wiley and Sons Ltd
Loss of expression of the intercellular adhesion molecule E-cadherin frequently occurs in invasive lobular breast carcinomas as a result of mutational inactivation. Expression patterns of E-cadherin and the molecules comprising the cytoplasmic comple
Autor:
B J, VOS, L H, WELSH
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 85
Autor:
A. M. Cleton-Jansen, Geert Berx, M.J. van de Vijver, C. B. J. Vos, F. Van Roy, Johannes L. Peterse, W. J. F. De Leeuw, N. ter Haar, Cees J. Cornelisse
Publikováno v:
British journal of cancer, 76(9), 1131-1133. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer
In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to
Publikováno v:
Transplantation. 64(8)
Graft-versus-host disease (GVHD) remains the most significant obstacle to the use of allogeneic bone marrow transplantation as a treatment for leukemia and other hematological malignancies. Because current GVHD treatment regimens such as cyclosporine
Publikováno v:
European Journal of Cancer. 33:S67
Autor:
M.J. van de Vijver, L.J.C.M. van der Broek, Johannes L. Peterse, C. B. J. Vos, C.J.H. van de Velde, N. ter Haar, P. C. Clahsen, W. J. F. De Leeuw
Publikováno v:
European Journal of Cancer. 32:7
Autor:
Peter Devilee, P. Meera Khan, A-L Børresen, C. B. J. Vos, M.J. van de Vijver, M. van Vliet, A-M. Cleton-Jansen, Hans J. Peterse, C.J. Cornelisse, R.S. Cornelis
Publikováno v:
Cancer Genetics and Cytogenetics. 77:170